Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bryan Arnold who wrote (4358)	5/20/1998 8:14:00 PM
From: Izzy	Read Replies (2) \| Respond to of 6136

Bryan, if you win my $175 million, I'll never speak to you again (but good luck anyway). MONEY magazine, June 1998, page 50, says that message boards (SI, etc.) "bring power to the people via collaborative research...isn't just about information; it's about providing an investor support group in good times and bad." Well, VectorVest stock analysis indicates that AGPH is undervalued (based primarily on growth to P/E ratio). AGPH has over $115 million in cash and essentially no significant debt. The stock closed at 35 today. ENMD closed at 33, VRTX closed at 27 3/4, NEOT closed at 19 1/4 (up 9+); and, they all have deficits and no revenues, quite unlike AGPH, which is making hundreds of millions of dollars. I really don't understand these stock valuations and why ML would give a 12-18 mos price target for AGPH at $40/sh (and not $50+). So, I guess I need some input, if any, from this fine support group. eom